DaisyShu
PhD
Location
Sydney, Australia
Current Organization
University of New South Wales
Biography
Dr. Daisy Shu is a Scientia Senior Lecturer at the University of New South Wales and an emerging leader in retinal disease research. With a clinical background in optometry and over a decade of research experience, her work focuses on age-related macular degeneration (AMD), retinal fibrosis, inflammation, angiogenesis, and mitochondrial dysfunction. She leads a multidisciplinary program that integrates retinal biology, chemical engineering, and drug delivery to develop innovative treatments for blinding retinal diseases. A former BrightFocus Foundation Postdoctoral Fellow, Dr Shu is now a recipient of their prestigious New Investigator Grant. She currently serves as Vice President of the International Society for Eye Research (ISER) and mentors early-career scientists through the Women’s Leadership Development Program of the Association for Research in Vision and Ophthalmology (ARVO), reflecting her strong commitment to supporting and empowering women in vision science.
Grants
Macular Degeneration Research
New Drug Delivery Approach to Transform Macular Degeneration Treatment
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
New Drug Delivery Approach to Transform Macular Degeneration Treatment
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
Macular Degeneration Research
Interplay Between Inflammation and Cell Metabolism in AMD
Active Dates
July 01, 2021 - July 31, 2023
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
Interplay Between Inflammation and Cell Metabolism in AMD
Active Dates
July 01, 2021 - July 31, 2023
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
News Featuring This Grantee
Research News
Transforming Macular Degeneration Care With Long-Acting Treatment
With funding from Macular Degeneration Research, Dr. Daisy Shu is exploring advanced drug delivery systems that release medicine slowly over time. This innovative approach could reduce the number of injections needed for macular degeneration while maintaining vision-saving results.
Research News
Is Inflammation the Answer? A Potential Future Treatment for Age-Related Macular Degeneration
Learn about a drug approved to treat autoimmune diseases such as psoriasis and multiple sclerosis that has shown promise in blocking inflammation linked to age-related macular degeneration.